Ropivacaine represses the proliferation, invasion, and migration of glioblastoma via modulating the microRNA-21-5p/KAT8 regulatory NSL complex subunit 2 axis

Deng, Zexiang; Jian, Yanping; Cai, Hongwei

doi:10.1080/21655979.2022.2037955

Cited by 3 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86 Lidocaine also interferes with the regulation of circular RNA (circRNA), microRNA (miRNA) and messenger RNA (mRNA) species affecting cellular development and progression at all levels. 87–91 Ropivacaine induces cell cycle arrest in cervical cancer cells by inhibiting miR-96-mediated the maternally expressed gene 2/signal transducer and activator of transcription 3 (MEG2/pSTAT3) signaling, 92 triggers apoptosis in glioma cells by impacting on the miR-424-5p/SNHG16 axis, 93 retards invasion and migration of choriocarcinoma by modulating the opioid growth factor receptor pseudogene 1 (OGFRP1) lncRNA and the miR-4731-5p/hypoxia-inducible factor 3A (HIF3A) axis, 94 suppresses the proliferation of glioblastoma via an impact on the miR-21-5p/lysine acetyltransferase 8 (KAT8) axis 95 and represses the progression of breast cancer by regulating miR-27b-3p/Yes-associated protein 1 (YAP). 96 Moreover, lidocaine upregulates microRNA-493 and miR-30c and thus sensitizes melanoma and cutaneous carcinoma to 5-fluorouracil and cisplatin, respectively.…”

Section: Preclinical Investigationmentioning

confidence: 99%

Trial watch: local anesthetics in cancer therapy

Carnet Le Provost,

Kepp,

Kroemer

et al. 2024

OncoImmunology

View full text Add to dashboard Cite

Preclinical evidence indicates potent antitumor properties of local anesthetics. Numerous underlying mechanisms explaining such anticancer effects have been identified, suggesting direct cytotoxic as well as indirect immunemediated effects that together reduce the proliferative, invasive and migratory potential of malignant cells. Although some retrospective and correlative studies support these findings, prospective randomized controlled trials have not yet fully confirmed the antineoplastic activity of local anesthetics, likely due to the intricate methodology required for mitigating confounding factors. This trial watch aims at compiling all published preclinical and clinical research, along with completed and ongoing trials, that explore the potential antitumor effects of local anesthetics.

show abstract

Section: Preclinical Investigationmentioning

confidence: 99%

Trial watch: local anesthetics in cancer therapy

Carnet Le Provost,

Kepp,

Kroemer

et al. 2024

OncoImmunology

View full text Add to dashboard Cite

show abstract

Systematic characterization and biological functions of non‐coding RNAs in glioblastoma

et al. 2022

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most malignant and aggressive type of glioma. Non‐coding RNAs (ncRNAs) are RNAs that do not encode proteins but widely exist in eukaryotic cells. The common characteristics of these RNAs are that they can all be transcribed from the genome without being translated into proteins, thus performing biological functions, particularly microRNAs (miRNAs), long non‐coding RNAs (lncRNAs) and circular RNAs. Studies have found that ncRNAs are associated with the occurrence and development of GBM, and there is a complex regulatory network among ncRNAs, which can regulate cell proliferation, migration, apoptosis and differentiation, thus provide a basis for the development of highly specific diagnostic tools and therapeutic strategies in the future. The present review aimed to comprehensively describe the biogenesis, general features and functions of regulatory ncRNAs in GBM, and to interpret the potential biological functions of these ncRNAs in GBM as well as their impact on clinical diagnosis, treatment and prognosis and discusses the potential mechanisms of these RNA subtypes leading to cancer in order to contribute to the better design of personalized GBM therapies in the future.

show abstract

Impact of local anesthetics on epigenetics in cancer

2022

View full text Add to dashboard Cite

Defective silencing of tumor suppressor genes through epigenetic alterations contributes to oncogenesis by perturbing cell cycle regulation, DNA repair or cell death mechanisms. Reversal of such epigenetic changes including DNA hypermethylation provides a promising anticancer strategy. Until now, the nucleoside derivatives 5-azacytidine and decitabine are the sole DNA methyltransferase (DNMT) inhibitors approved by the FDA for the treatment of specific hematological cancers. Nevertheless, due to their nucleoside structure, these inhibitors directly incorporate into DNA, which leads to severe side effects and compromises genomic stability. Much emphasis has been placed on the development of less toxic epigenetic modifiers. Recently, several preclinical studies demonstrated the potent epigenetic effects of local anesthetics, which are routinely used during primary tumor resection to relief surgical pain. These non-nucleoside molecules inhibit DNMT activity, affect the expression of micro-RNAs and repress histone acetylation, thus exerting cytotoxic effects on malignant cells. The in-depth mechanistic comprehension of these epigenetic effects might promote the use of local anesthetics as anticancer drugs.

show abstract

Ropivacaine represses the proliferation, invasion, and migration of glioblastoma via modulating the microRNA-21-5p/KAT8 regulatory NSL complex subunit 2 axis

Cited by 3 publications

References 52 publications

Trial watch: local anesthetics in cancer therapy

Trial watch: local anesthetics in cancer therapy

Systematic characterization and biological functions of non‐coding RNAs in glioblastoma

Impact of local anesthetics on epigenetics in cancer

Contact Info

Product

Resources

About